MedinCell S.A. Logo

MedinCell S.A.

Develops long-acting injectable therapies using proprietary technology to impact global health.

MEDCL | PA

Overview

Corporate Details

ISIN(s):
FR0004065605
LEI:
969500R79U6PXCL2FF46
Country:
France
Address:
3 RUE DES FRERES LUMIERE, 34830 JACOU
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MedinCell S.A. is a clinical and commercial-stage pharmaceutical company specializing in the development of long-acting injectable (LAI) therapies. Leveraging its proprietary drug delivery technology, the company develops a diverse portfolio of controlled-release products across various therapeutic areas. This innovative approach is designed to enhance treatment efficacy, improve patient compliance, and reduce the overall burden of care by providing sustained therapeutic effects from a single injection. MedinCell collaborates with global pharmaceutical partners to advance its pipeline and address unmet medical needs, with a core mission to impact global health by making treatments more efficient and accessible.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-05 13:46
Earnings Release
Informations privilégiées / Autres communiqués
French 310.2 KB
2025-11-05 13:46
Earnings Release
Inside Information / Other news releases
English 215.5 KB
2025-09-22 07:30
Regulatory Filings
Informations privilégiées / Autres communiqués
French 359.5 KB
2025-09-22 07:30
Regulatory Filings
Inside Information / Other news releases
English 263.8 KB
2025-09-12 07:30
Board/Management Information
Informations privilégiées / Autres communiqués
French 189.0 KB
2025-09-12 07:30
Board/Management Information
Inside Information / Other news releases
English 178.3 KB
2025-09-10 21:41
Regulatory Filings
Informations privilégiées / Autres communiqués
French 171.5 KB
2025-09-10 21:41
Regulatory Filings
Inside Information / Other news releases
English 168.1 KB
2025-06-17 17:45
Annual / Quarterly Financial Statement
Inside Information / News release on accounts, results
English 405.2 KB
2025-06-17 17:45
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 395.7 KB
2025-06-10 18:00
Report Publication Announcement
Inside Information / Other news releases
English 185.6 KB
2025-06-10 18:00
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 192.0 KB
2025-06-06 18:00
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 183.7 KB
2025-05-28 18:00
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 183.1 KB
2025-05-28 18:00
Regulatory Filings
Inside Information / Other news releases
English 156.6 KB

Automate Your Workflow. Get a real-time feed of all MedinCell S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MedinCell S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MedinCell S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-05-02 N/A Other Sell 60,000 600,006.00 EUR

Peer Companies

JEIL PHARMA HOLDINGS INC. Logo
Develops and distributes APIs, generics, and modified drugs, specializing in injections.
South Korea
002620
JETEMA Co.,Ltd. Logo
Research-driven developer of aesthetic toxins, dermal fillers, and threads.
South Korea
216080
Develops and manufactures high-tech drugs for cancer, diabetes, and a range of diseases.
South Korea
007370
JOHNSON & JOHNSON Logo
Develops innovative medicines and medical technologies for complex diseases and personalized care.
United States of America
JNJ
Journey Medical Corp Logo
A pharmaceutical firm commercializing prescription drugs and generics for dermatology.
United States of America
DERM
JUPITER NEUROSCIENCES, INC. Logo
Pharma firm developing resveratrol treatments for neuroinflammation and rare diseases.
United States of America
JUNS
JW LIFESCIENCE CORPORATION Logo
A leading developer and manufacturer of infusion solutions, from basic IV fluids to complex nutrients.
South Korea
234080
JW SHINYAK CORPORATION Logo
Develops specialty medicines for the dermatology, urology, and otolaryngology clinical markets.
South Korea
067290
Jyong Biotech Ltd. Logo
Develops plant-derived drugs for urinary system diseases, with a lead candidate in Phase III trials.
United States of America
MENS
Kadimastem Ltd. Logo
Develops off-the-shelf stem cell therapies for diabetes & neurodegenerative diseases.
Israel
KDST

Talk to a Data Expert

Have a question? We'll get back to you promptly.